Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk trims forecast on US headwinds

This article was originally published in Scrip

Executive Summary

Novo Nordisk has reported weaker than expected first quarter results. Sales grew by 7% in local currencies to DKK20.3bn, meaning the world's biggest insulin manufacturer failed to report quarterly double-digit sales growth for the first time in 12 years. The Danish company has now trimmed its forecast for full-year sales growth from 8-11% to 7-10%.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts